98%
921
2 minutes
20
Diving bradycardia is a reduction in the heart rate mediated by the parasympathetic system during diving. Although diving bradycardia is pronounced in aquatic mammals and birds, the existence of this response in aquatic reptiles, including sea turtles, remains under debate. Using the parasympathetic blocker atropine, we evaluated the involvement of the parasympathetic nervous system in heart rate reduction of loggerhead sea turtles (Caretta caretta) during voluntary diving in tanks. The heart rate of the control group dropped by 40-60% from the pre-dive value at the onset of diving; however, administration of atropine significantly inhibited heart rate reduction (P<0.001). Our results indicate that, similar to mammals and birds, the heart rate reduction in sea turtles while diving is primarily mediated by the parasympathetic nervous system. In conclusion, we suggest that diving bradycardia exists not only in aquatic mammals and birds but also in aquatic reptiles.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1242/jeb.243922 | DOI Listing |
Endocrine
September 2025
Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Phys Eng Sci Med
September 2025
Department of Radiology, Otaru General Hospital, Otaru, Hokkaido, Japan.
In lung CT imaging, motion artifacts caused by cardiac motion and respiration are common. Recently, CLEAR Motion, a deep learning-based reconstruction method that applies motion correction technology, has been developed. This study aims to quantitatively evaluate the clinical usefulness of CLEAR Motion.
View Article and Find Full Text PDFDrug Dev Ind Pharm
September 2025
Jiangsu Medical College, Yancheng, 224005, China.
Objective: To prepare astragaloside IV dripping pills (ASDP) and assess their therapeutic effects on mice with doxorubicin hydrochloride-induced dilated cardiomyopathy (DCM).: Astragaloside IV (AS) exhibits pharmacological effects in treating cardiovascular diseases, however, its clinical application is hindered by poor solubility and low bioavailability. The study sheds light on new therapeutic strategy of DCM and development of AS formulations.
View Article and Find Full Text PDFEur Heart J
September 2025
Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Venusberg-Campus 1, Bonn 53127, Germany.
Background And Aims: Fulminant myocarditis (FM) is a complex clinical syndrome characterized by acute myocardial inflammation and cardiogenic shock. Evidence on long-term outcomes, mortality risk factors, and targeted treatment options remains limited.
Methods: This retrospective analysis included consecutive adult patients admitted for FM between January 2012 and November 2022 at 26 European tertiary centres.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Sepsis remains a leading cause of critical illness and mortality worldwide, driven by a dysregulated host response to infection and often complicated by persistent tachycardia and cardiovascular dysfunction. Increasing evidence implicates excessive sympathetic activation as a contributor to sepsis-related hemodynamic instability and myocardial injury, prompting growing interest in the use of β-adrenergic blockade as a therapeutic adjunct. This review synthesizes current data on the safety and efficacy of short-acting, cardioselective β-blockers (BBs), particularly esmolol and landiolol, in septic shock.
View Article and Find Full Text PDF